Anixa Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $210K0.0% YoYTTM through 30 Apr 2026
Net Income -$5.1MTTM through 30 Apr 2026
Free Cash Flow -$7.1MTTM through 30 Apr 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
| Operating Margin | -2,553.8% |
| Net Margin | -2,419.5% |
Returns
-69.9%ROE
-68.1%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio9.79x
Net Debt-$13.7Mnet cash position
Cash & Equivalents$1.5M
Quality Metrics
FCF Margin-3,390.5%
Earnings-Beat Rate75.0%
Dividend
No dividend
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.